Testing a new medicine for advanced liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests a new treatment (BGB-B2033) for advanced liver cancer that has returned or not responded to previous immune therapy. It compares this new drug to the standard options sorafenib or lenvatinib, which are targeted pills. The goal is to see if BGB-B2033 can help shrink or slow the cancer better than the current treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You were diagnosed with a type of liver cancer called hepatocellular carcinoma (HCC).
- Your cancer cannot be removed with surgery or treated only with local treatments like radiation or injections into the liver.
- You have already tried at least one or two rounds of a treatment that helps your immune system fight cancer (called a PD-1/PD-L1 inhibitor), and your cancer either got worse or you couldn't handle the side effects.
- You have not had a liver transplant or serious liver problems like severe fluid in the belly or episodes of confusion from liver failure.
- You are still able to do most of your daily activities on your own.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called BAY 3547926 for people with advanced liver cancer that cannot be removed with surgery or has not responded to other treatments. The goal is to see if the drug is safe and how well it works.
This trial tests a new medicine, PF-08634404, alone or with other treatments for adults with advanced liver cancer that cannot be removed by surgery or has spread. It is for people who have not had prior systemic therapy and have good liver function.
This trial tests a combination of immunotherapy (anti-PD-1/PD-L1) and an anti-VEGF drug for people with advanced hepatocellular carcinoma (HCC), a type of liver cancer that cannot be removed by surgery or has spread. The goal is to see if these drugs can shrink tumors or slow the cancer's growth.
This trial tests a combination of two drugs (lenvatinib and toripalimab, a type of immunotherapy) plus a special chemotherapy infusion directly into the liver artery for people with advanced liver cancer that has not been treated before. The goal is to see if adding the immunotherapy helps shrink tumors better than the standard combination.
This study tests a combination of two drugs—lenvatinib (a targeted therapy that blocks blood vessel growth) and tislelizumab (an immunotherapy that helps your immune system fight cancer)—in people with advanced liver cancer who also have hepatitis B. The goal is to see if this combination can shrink tumors or slow the cancer's growth, and to find biomarkers (clues in your blood or tissue) that predict who will benefit.
This trial tests a new combination of three drugs for people with advanced liver cancer whose disease got worse after their first treatment. The goal is to see if this new mix can help control the cancer better and give patients more time.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.